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ABSTRACT 
Objective: The aim of the research work is to formulate emulgel of Meloxicam for topical application.  
Methods: The method used for preparation of microemulsion was water titration method with Oleic acid as oil phase, Tween 20 as surfactant and 
PEG 400 as co-surfactant and its concentrations were fixed based on Pseudoternary phase diagrams. The optimized emulsion formulation was 
incorporated into the gel matrix that is Carbopol981 NF and Carbopol 974 P NF.  
Results: The prepared emulsions were characterized for globule size, drug content, zeta potential and the emulgel for physical appearance, drug 
content, pH, viscosity, spreadability, extrudability and in vitro drug release studies. The optimized emulsion formulations E1 and F1 showed globule 
size of 176 nm and 128 nm respectively and the emulgel formulation M2F1 with 1.5% Carbopol 981 and optimized F1 emulsion formulation 
showed in vitro drug release of 89.934% at the end of 8 h. The optimized formulation showed no skin irritation when compared with standard 
irritant 0.8% of Formalin. The optimized formulation showed better anti-inflammatory effect when compared with marketed formulation. 
Conclusion: Meloxicam was proven to be a suitable candidate for formulating emulgel for topical delivery to achieve better patient compliance.  
Keywords: Meloxicam, Emulgel, Topical application, Carbopol 981NF, Carbopol 974 P NF, Oleic acid, Tween 20 and PEG 400. 
 
INTRODUCTION 
Meloxicam is a non-steroidal anti-inflammatory agent with analgesic 
and anti-inflammatory effect, used for the treatment of rheumatoid 
arthritis and osteoarthritis. Meloxicam belongs to the class of 
preferential COX-2 inhibitors. It is a newer congener of Piroxicam. 
Meloxicam is a poorly water soluble drug having solubility of 7.15 
mg/l and protein binding of 99.4% and it exhibits gastrointestinal 
side effects like gastric bleeding, ulceration and perforation of 
stomach, small and large intestine when given orally [1]. 
Topical delivery can be defined as the application of drug containing 
formulation to skin to directly treat the cutaneous disorders or the 
cutaneous manifestation of general disease with the intent of 
confining the pharmacological or other effect of the drug to the 
surface of skin or within the skin. Most widely used semisolid 
preparations includes gel, creams, ointments etc 
The U. S. P defines gel as a semisolid system consisting of dispersions 
made up of either small inorganic particles or large organic molecules 
enclosing and interpenetrated by liquid. The gel contains the larger 
amount of aqueous or hydroalcoholic liquid in a network of colloidal 
solid particles which may consist of inorganic or organic substances. 
Inspite of many advantages of gels a major limitation is in the delivery 
of hydrophobic drugs. So to over this limitation an emulsion based 
approach is being used so that even a hydrophobic therapeutic moiety 
can enjoy the unique properties of gels. 
When emulsions and gels are used in combined form, the dosage 
form is referred to as “Emulgel”. The presence of gelling agent in the 
water phase converts the classical emulsion into an emulgel. The 
Emulgel are hydrogel containing randomly distributed oil micro 
droplets. 
Emulsions are biphasic systems in which one immiscible liquid is 
dispersed into other due to which the system becomes unstable and 
so stabilized by adding an emulsifying agent. Emulsion itself is a 
controlled release system where entrapped drug particles in 
internal phase passes through the external phase and then slowly 
gets absorbed into the skin. The gel forms a cross linked network 
where it captures small drug particles and provides its release in a 
control manner. 
Emulgel are emulsions either oil-in-water or water-in-oil type which 
are gelled by mixing with a gelling agent. They have high patient 
acceptability because of its favorable properties such as being 
thixotropic, grease less, easily spreadable, easily removable, 
emollient, nonstaining, long shelf life, biofriendly, transparent and 
pleasing appearance [2, 3]. 
Microemulsions are homogeneous, transparent, thermodynamically 
stable dispersions of water and oil stabilized by addition of 
surfactant, usually in combination with co-surfactant and whose 
droplet size is in the range of 20-200 nm. Since microemulsions have 
large surface area, they can incorporate in their core larger 
quantities of molecules which are insoluble in the continuous phase. 
The main difference between emulsion and microemulsion is the 
size and the shape of the droplets and since the size of the droplets 
in microemulsion is much smaller than the wavelength of visible 
light the microemulsions are transparent. The microemulsions are 
prepared with high concentration of surfactant which is useful in the 
greater stabilization of hydrophobic drugs and also requires lesser 
amount of energy.  
To overcome the disadvantages of Meloxicam in the oral delivery an 
attempt has been made in the present study to formulate emulgel of 
Meloxicam by incorporating microemulsion of Meloxicam in the gel base. 
MATERIALS AND METHODS 
Materials used 
Meloxicam was obtained as a gift sample from Unichem Laboratories 
Pvt limited Goa India. Carbopol 981NF and 974 P NF were obtained 
as the gift sample from Lubrizol Mumbai India. Oleic acid was 
obtained from Merck Specialist Mumbai India. Tween 20 and PEG 
400 were obtained from Hi-media Mumbai India. All the other 
chemicals and reagents used were of analytical grade. 
Methods 
Saturation solubility in oils, surfactant and co-surfactant 
Excess amount of drug was added to 10 ml vials containing 10 ml of 
oil (Castor oil, sunflower oil, olive oil and oleic acid), Surfactants 
(Tween 20,Tween 60, Tween 80, Span 20 and Span 80) and co-
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surfactants (PEG 400, PEG 600 and Propylene Glycol) respectively 
and then it was kept on a mechanical shaker for 72 h. After 72 h 
solution were centrifuged for 10 min at 3000 rpm and then the 
supernatant was filtered and UV absorbance was taken at 341 nm by 
suitable dilution with Chloroform [4, 5]. 
Construction of pseudoternary phase diagrams 
Pseudoternary phase diagrams were constructed using Chemix 
school 3.60 software. The method used for the study was water 
titration method and it helps to determine the concentration range 
of components for the existing range of microemulsion. Three phase 
diagrams were prepared with 1:1, 2:1 and 3:1 ratio of Tween 20 to 
PEG 400 respectively. The mixture of oil, surfactant and co-
surfactant at certain weight ratios was diluted with water drop-wise, 
by vortexing with vortex mixture after being equilibrated, the 
mixtures were assessed visually and determined as being micro 
emulsion, crude emulsions or gel [6]. 
Preparation of emulsion 
Meloxicam was dissolved in the mixture of oil, surfactant, and co-
surfactant with varying component ratio as shown in the table 1 and 
then an appropriate amount of water was added to the mixture drop 
by drop while continuous stirring with magnetic stirrer at ambient 
temperature, until a clear phase was obtained [7]. 
 









Amount of drug 
added (mg) 
Approx. theoretical 
drug content (mg) 




1 E1 1:1 1:9 200 217.209 10  5 
2 E2 1:1 2:8 200 199.39 10  2.3 
F E3 1:1 3:7 200 181.55 10  1.3 
4 F1 2:1 1:9 200 202.24 10  10  
5 F2 2:1 2:8 200 219.723 10  2.5 
6 F3 2:1 3:7 200 201.37 10  1.8 
7 G1 3:1 1:9 200 220.96 10  35 
8 G2 3:1 2:8 200 154.032 10  5 
9 G3 3:1 3:7 200 195.63 10  1.4 
 
Characterization of emulsion 
The prepared emulsion formulations of emulsions were evaluated 
for drug content, Globule size and Zeta potential. 
Drug content of emulsion 
1 ml of emulsion was taken and added to 10 ml volumetric flask, 
with making up its volume and further dilutions with chloroform 
and UV absorbance was taken at 341 nm. The microemulsion 
without drug was used as a blank. The values obtained were used to 
calculate the concentration of drug in emulsion [8]. 
Globule size determination 
The globule size distribution of the formulations was measured by 
Nanotrac particle size analyzer [Microtrac/Nanotrac A150, Korea]. 
0.1 ml of the emulsion was taken and it was diluted to 250 ml with 
distilled water and then the readings were taken. 
Zeta potential 
Zeta potential of all the formulations was measured by using Zeta 
meter instrument [UNITRON FSB (4X) Japan] 
Formulation of emulgel 
The Carbopol 981 NF and 974 P NF in the concentration of 1.5% 
and 2% were swelled in distilled water and the optimized 
emulsion formulation was added to the gel base. The emulsion 
equivalent to 0.5% of Meloxicam was added to the gel base. The 
pH was adjusted using Triethanolamine; glycerin was added as 
humectant and Methyl paraben, Propyl paraben as the 
preservatives. 
 
Table 2: Formulation table of emulgel containing Meloxicam 
Ingredients M1E1 M2F1 M’1E1 M’2F1 NIE1 N2F1 N’1E1 N’2F1 
Meloxicam emulsion equivalent to 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 
Carbopol 981 1.5% 1.5% 2% 2%     
Carbopol 974     1.5% 1.5% 2% 2% 
Glycerin 1% 1% 1% 1% 1% 1% 1% 1% 
Triethanol amine 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 0.02% 
Methyl Paraben 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 
Propyl Paraben 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 0.03% 
Distilled water q. s 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 100 ml 
 
Characterisation of emulgel 
Physical examination 
The prepared Emulgel formulations were inspected visually for their 
color, homogeneity and consistency. 
Drug content 
1 gm of emulgel was accurately weighed and dissolved in 100 ml of 
chloroform and it was kept for sonication for 2 h. The solution was 
passed through filter paper and filtered. The absorbance was 
measured spectrophotometrically at 341 nm against corresponding 
Emulgel without drug as blank. Drug content was calculated using 
the slope and the intercept obtained by linear regression analysis of 
the standard calibration curve. All the measurements were carried 
out in triplicates [9]. 
pH 
The pH of various emulgel formulations was determined by using 
digital pH meter. 1 gm of emulgel was dissolved in 100 ml of distilled 
water and stored for 2 h. The measurements were carried out in 
triplicates. 
Viscosity 
The measurement of the viscosity of the prepared emulgel was done 
with a Brookfield Rheometer. The emulgel was rotated at 1rpm and 
the corresponding dial reading was noted. The viscosity of the gel 
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was obtained by that reading. The viscosity was measured in cPs. 
The measurements were carried out in triplicates [10]. 
Spreadability 
It indicates the extent of the area to which emulgel readily spreads 
on application to skin or affected part. The spreadability was 
performed by taking two slides of 5 cm each. The down slide which 
was kept fixed, 1 gm of emulgel was placed on it and the other slide 
was kept on top of it and weight of 5 gms was placed on top of upper 
slide and it was kept in the same position for 5 min. The weight was 
removed and the time required to remove the upper slide was noted 
down. Lesser the time taken for the separation of two slides, better 





Where, M = weight tied to upper slide 
L = length of glass slide 
T = time taken to separate the slides [11] 
Extrudability 
Extrudability test is based upon the determination of weight 
required to extrude 0.5 cm ribbon of emulgel in 10 sec from 
lacquered collapsible aluminum tube. The test was performed in 
triplicate and the average values were calculated. The extrudability 
was then calculated by using the following formula. [12] 
Extrudability =
weight applied to extrude emulgel from tube(gm)
Area(cm²)
 
In vitro release study 
The in vitro drug release studies of the Emulgel were carried out in 
modified Franz Diffusion cell using the dialysis membrane. Emulgel 
(1 gm) was spread uniformly on the dialysis membrane. 50 ml of the 
Phosphate buffer of pH 6.8 was used as dissolution media which 
were added to the receptor compartment. This whole assembly was 
kept on a magnetic stirrer and the solution on the receptor side was 
stirred continuously using a magnetic bead and temperature of the 
cell was maintained at 37±0.5 °C Sample (1 ml) was withdrawn at 
suitable time intervals and replaced with the equal amounts of fresh 
dissolution media. Samples were analyzed spectrophotometrically at 
361 nm and the cumulative % drug release was calculated. The 
study was carried out in triplicates. The graph is plotted of % 
cumulative drug releases versus time [11]. 
Drug release kinetics 
To analyze the mechanism for the release and release rate kinetics of 
the dosage form, the data obtained from the in vitro diffusion study 
were fitted in to Zero order, First order, Higuchi matrix and 
Korsmeyer-Peppas model. By comparing the R2
Skin irritation test 
 values obtained, the 
best fit model was selected.  
The skin irritation test was performed on the male Wistar rat. Prior 
to the experiment ethical clearance was obtained from institutional 
ethical committee [Resolution no KLECOP/IAEC/Re.20-09/08/ 
2014]. The animals were divided in three groups i.e. control, 
standard and test. The back skin of the rat of 5 cm2
In vivo anti-inflammatory study 
 was shaven one 
day prior to the starting of the study. After 24 h of shaving the skin 
of rat, the standard group was applied with 0.8% of Formalin which 
is the standard irritant and the test group was applied with the 
optimized formulation M2F1 and the rats were observed for any 
irritation at the end of 24 h the animals were observed for erythema 
or edema and score were given accordingly. If the formulation 
produces score of 2 or less than 2 no irritation persists [13]. 
In vivo anti-inflammatory study was carried out on Wistar rats as 
animal model weighing approximately 200-250 gms each. For the 
study animals were divided into three groups i.e. the Control, 
Standard and test. Each group containing 6 animals each. 
GROUP I (Control Group): Carragenan (1%) was administered in the 
plantar surface of rat. 
GROUP II (Standard group): Topical marketed Piroxicam gel (Pirox 
gel)+Carragenan. 
GROUP III (Test Group): Optimized formulation M2F1+Carragenan 
Edema was induced on the left hind paw of the rats by subplantar 
injection of 1% Carragenan. The test formulation i.e. M2F1 and 
Standard i.e. Pirox gel were applied 30 min before carrageenan 
administration. The paw volume was measured at intervals of 30, 
60, 90, 120, 150 and 180 min by mercury displacement method 
using Plethysmometer. 
The percentage inhibition of paw edema in drug treated group was 
compared with Carragenan control group and calculated according 
to the formula:  




Vc = inflammatory increase in paw volume of control group  
Vt= inflammatory increase in paw volume in (drug+Carragenan) 
treated animals [14]. 
Stability studies 
Short term stability study was performed on the optimized 
formulation. The formulation was subjected to different conditions 
of temperature and relative humidity i.e. 25oC/60% RH and 40 o
RESULTS AND DISCUSSION 
C/ 
65% RH for a period of 2 mo. Samples were withdrawn at the 
interval of 1 mo and were evaluated for rheological properties, drug 
content and %CDR [15]. 
Saturation solubility in oils, surfactants and co-surfactants 
Inorder to screen appropriate solvents for the preparation of emulsion, 
the solubility of Meloxicam in various oils, surfactants and co-surfactants 
was carried out and the obtained results were summarized in fig. no: 1-3. 
The solubility in oleic acid was found to be 5.664 mg/ml and that in 
surfactant i.e. Tween 20 is 24.336 mg/ml and in case of co-surfactants i.e. 
PEG 400 is 22.68 mg/ml. Among the various oils used the highest 
solubility was found in case of Oleic acid, Tween 20 has the highest 
solubility among surfactant and PEG 400 among the co-surfactant. So 
based on the solubility the oil i.e. oleic acid, Tween 20 and PEG 400 were 
selected for the preparation of emulsion. 
 
 
Fig. 1: Saturation solubility of Meloxicam in oils 
 
Construction of Pseudoternary phase diagram 
The region shaded yellow showed the transparent microemulsion 
region in the phase diagram. The microemulsion region for the 
surfactant: co-surfactant ratio 3:1 was found to be the largest and 
lowest for the 1:1 ratio. The results were shown in fig. no 4. The area 
of microemulsion increased as the concentration of surfactant 
increases possibly because Tween 20 is a non-ionic solvent that 
forms clear solution in water, so the area of o/w microemulsion was 
increased. The largest microemulsion region was obtained for the 
surfactant: co-surfactant ratio of 3:1 and smallest microemulsion 
Pednekar et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 11, 216-222 
219 
area was obtained for the ratio 1:1 and it was observed that as the 
concentration of surfactant increases the quantity of water required 
to obtain turbidity also increases and as more the water quantity 
required the solubility of drug also decreases. On the basis of 
stability the first three ratios of oil: Smix was selected from each 
ratio of surfactant: co-surfactant [8]. 
 
Fig. 2: Saturation solubility of Meloxicam in surfactants 
 
Drug content 
The drug content varied from 75.48% to 93.31%. The formulation 
E1 showed drug content of 93.31%, F1 was 92.34% and G1 was 
91.76%. The highest drug content was found in case of E1 
formulation due to greater solubilization of drug as compared to 
others and even as the quantity of water required to form the 
microemulsion was less in case of 1:1 ratio of surfactant: co-
surfactant and 1:9 ratio of oil: Smix. 
Globule size determination 
The globule size of all the prepared microemulsion was evaluated on 
Nanotrac. The globule size obtained was reported in the table no: 3. 
On the basis of result obtained it was found that the globule size 
decreased as the surfactant concentration increased. The lowest 
globule size was obtained for the microemulsion formulation G1i.e. 
17.93 nm and the globule size of the formulations E1 and F1 were 
found to be 176.8 nm and 128 nm respectively. The formulation E1 
and F1 was selected as optimized microemulsion formulation based 
on globule size as it was ranging in microemulsion region and there 
was not much difference in the drug content of the two formulations. 
The formulation G1 though had lowest particle size was not selected 
as optimized as it was falling in nanoemulsion range and since 
nanoemulsions are thermodynamically unstable compared to the 
microemulsions. 
 
Fig. 3: Saturation solubility of Meloxicam in co-surfactants. 
 
Characterisation of Emulsion 
Zeta potential determination 
The Zeta potential of all formulations was found to be in the range 
of-27.6 to-53.73. Based on the result of the zeta potential the 
formulations were found to show moderate to good stability [16]. 
 
   
Fig. 4: Pseudoternary Phase diagram of surfactant: co-surfactant ratio of 1:1, 2:1 and 3:1 with oil: Smix in the ratios ranging from 1:9 to 9:1 
 
Table 3: Evaluation parameters of Meloxicam emulsion 
Formulation code Drug content (%)* Globule size (nm) Zeta potential* 
E1 93.31±1.22  176.8 -53.73±1.28 
E2 90.40±0.77  399 -41.2±1.35 
E3 88.6±2.34  504 -34.5±3.76 
F1 92.34±4.08  128 -50.6±0.46 
F2 87.6±1.94  338 -38.3±0.96 
F3 87.2±4.37  454 -27.6±0.44 
G1 91.76±1.59  17.93 -43.28±1.62 
G2 75.48±4.19  202.4 -31.65±0.55 
G3 86.8±2.26  347 -28.56±0.88 
*All values are expressed as mean±SD(n=3) 
 
Characterization of Emulgel 
Appearance, Drug content and pH: All the prepared formulations 
were pale yellow in appearance and they showed good homogeneity 
and consistency. The percentage drug content of prepared emulgel 
was found in the range of 90.51 to 94.98%. The results were 
depicted in the table 4. The highest drug content i.e. 94.98% was 
obtained for the formulation M2F1 containing optimized F1 
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formulation of emulsion and gelling agent present in the 
concentration of 1.5% of Carbopol 981. The pH of all the formulation 
was found to be ranging from 6.54 to 6.94 which were found to be 
acceptable to avoid any skin irritation as shown in fig. 5. All the 
formulations were free of any lumps and grittiness. The highest drug 
content i.e. 94.98% was obtained for the formulation M2F1 
containing optimized F1 formulation of emulsion and gelling agent 
present in the concentration of 1.5% of Carbopol 981. 
 
Table 4: Appearance and drug content of Meloxicam Emulgel 
Formulation code Appearance Drug content (%)* 
M1E1(1.5% Carbopol 981) Pale yellow 94.18±3.713 
M2F1(1.5% Carbopol 981) Pale yellow 94.98±5.074 
M’1E1(2%Carbopol 981) Pale yellow 92.38±2.153 
M’2F1(2% Carbopol 981) Pale yellow 92.78±2.645 
P1E1(1.5% Carbopol 974) Pale yellow 90.51±1.43 
P2F1(1.5% Carbopol 974) Pale yellow 93.59±5.256 
P’1E1(2% Carbopol 974) Pale yellow 91.18±1.707 
P’2F1(2% Carbopol 974) Pale yellow 91.98±1.361 
*All values are expressed as mean±SD(n=3) 
 
 
Fig. 5: pH of emu gel formulations M1E1 to P’2F1 
 
Viscosity determination 
Viscosities of all the prepared emu gel formulations are shown in fig. 6 
the results showed that the emu gel formulation M2F1 showed the 
lowest viscosity of 12420 cPs and highest viscosity was obtained for 
P’1E1 i.e. of 37550 cPs. The P’2F1 showed viscosity of 35420, P1E1 
and P2F1 showed 31450 and 30100 cPs respectively. The same way 
M1E1, M’1E1 and M2F1 showed viscosity of 13450, 20105 and 18430 
cPs respectively. The emu gel formulation M2F1 containing 1.5 % of 
Carbopol 981 and optimized emulsion formulation F1 showed the 
lowest viscosity. It was found that as polymer concentration increases 
viscosity also increases. The F1 microemulsion formulation contains 
the larger surfactant concentration as compared to the E1 so its 
viscosity decreases as mentioned by Ghodekar et al. in his work 
antifungal activity of microemulsion based fluconazole gel. So higher 
the concentration of surfactant and lower the concentration of gelling 
agent lower the viscosity. As the concentration of polymer increases to 
2% the viscosity also increases. The viscosity of formulation 
containing Carbopol 974 was more than the one containing Carbopol 
981 [13, 15]. 
 
 
Fig. 6: Viscosity of emulgel formulations M1E1 to P’2F1 
Spreadability 
The spreadability value of all the prepared emu gel was depicted in 
the fig. 7. The formulation M2F1 having viscosity 12420 cPs has high 
spreading coefficient of 14.13. The other formulations showed 
M1E1, M’1E1, M’2F1, P1E1, P2F1, P’1E1 and P’2F1 showed 
spreadability of 13.24, 11.75, 12.18, 10.25, 10.75, 8.21 and 8.84 gm. 
cm/sec respectively. The spreadability is dependent on the 
concentration of polymer and viscosity of the formulation. The 
formulation M2F1 having viscosity 12420 cPs showed high 
spreading coefficient of 14.13. The viscosity increases as the 
concentration of polymer increases and as the spreadability is 
dependent on the viscosity so it increases as the viscosity decreases 
concluding that the formulation spreads well. The spreadability of 
formulation containing 2% concentration was found to be lower 
than the one containing 1.5% concentration of polymer. The 
spreadability of the formulations containing differs from polymer to 
polymer so the one containing Carbopol 974 spreads less than the 
one containing Carbopol 981.  
Extrudability 
The extrudability of the prepared emulgel is depicted in fig. 7. The 
formulation M2F1 has extrudability value of 15.52 gm/cm2 as its 
viscosity was 12420 cPs. The other formulations M1E1, M’1E1, 
M’2F1, P1E1, P2F1, P’1E1, P’2F1 showed extrudability value of 
13.53, 9.95, 10.75, 7.96, 7.16, 7.56 gm/cm2
 
 respectively. The 
extrudability is dependent on the viscosity of the polymer so as the 
viscosity increases extrudability decreases. As the viscosity depends 
on the type of polymer and its concentration and even on the 
surfactant concentration so the extrudability value of the 
formulation containing M1F1 was higher as compared to other 
formulations and the extrudability was found to be less for the 
formulation P’2E1 containing Carbopol 974 and E1 emulsion 
formulation. 
 
Fig. 7: Spreadability and Extrudability of emulgel formulation 
M1E1 to P’2F1 
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In vitro drug release 
The percentage cumulative drug release of all the prepared emulgel 
formulations at the end of 8 h is represented graphically in the fig. 8 
and 9. Maximum drug release was observed for the formulation 
M2F1 i.e. of 89.934% and minimum was obtained for P’1E1 i.e. of 
74.26 %. The pure drug showed release of 52.162% at the end of 8h. 
It is represented graphically in fig. no 10. Maximum drug release was 
observed for the formulation M2F1 i.e. of 89.934%. The reason 
attributed for a higher release is the lower concentration of gelling 
agent i.e. 1.5% of Carbopol 981 employed in that formulation and 
the concentration of the optimized microemulsion formulation F1 
which contains 2:1 ratio of surfactant and co-surfactant as the 
release of drug from microemulsion may be more because of the 
larger concentration of surfactant and even it has lower droplet size 
and as the release rate is inversely related to particle size i.e. smaller 
the droplet size higher the release.  
 
Fig. 8: In vitro release profile of M1E1 to M’2F1containing 
Carbopol 981 as gelling agent 
 
 
Fig. 9: In vitro release profile of P1E1 to P’2F1 containing 
Carbopol 974 as gelling agent 
 
 
Fig. 10: In vitro release profile of optimized formulation and 
pure drug 
 
The release is dependent on the polymer concentration and the 
viscosity of polymer. The formulation containing higher 
concentration of polymer will show lower percentage cumulative 
release as the concentration increases viscosity increases which 
retards the drug release. The percentage cumulative release of 
optimized formulation was compared with that of the pure drug 
incorporated into the Carbopol 981 gel base. The pure drug showed 
release of 52.162% at the end of 8 h, as the drug being water 
insoluble it may not have been properly dispersed in the gel base 
and so the release is retarded [9, 11]. 
In vitro drug release kinetics 
The best fit model in the optimized formulation was found to be the 
Korsmeyer Peppas and its n value is greater than 0.89it follows 
super case II transport i.e. the drug release doesn’t change over time 
and it involves polymer relaxation and chain disentanglement. The 
formulations P1E1 and P’1E1 follows zero order release pattern as 
the correlation coefficient values are higher in case of zero order and 
also the release rate is independent of the concentration of the drug. 
The other formulations showed Peppas as the best fit model. The n 
value of Korsmeyer Peppas is greater 0.5 so it follows the non-
fickian diffusion. The n value of Korsmeyer Peppas is greater than 
0.5 so it follows the non-fickian diffusion. ie drug release is both 
diffusion and erosion controlled mechanism [17, 18]. 
Skin irritation test 
The score given for the standard group was 2.5 and for test group 
was 0. In case of standard group, there was moderate erythema with 
barely perceptible edema was and the test group showed no 
irritation. As shown in fig. 11. Since no irritation persists the 
optimized formulation passes the skin irritation test. 
 
 
A-Control group after shaving, B-Control group after 24 h, C-
Standard group (0.8% Formalin), D-Standard group after 24 h 
of application of formalin, E-Test group after shaving, F-Test 
group 24 h after application of optimized M2F1 formulation 
Fig. 11: Skin irritation test on male Wistar Rats 
 
 
Fig. 12: Percentage inhibition of anti-inflammatory study of 
optimized Meloxicam loaded Emulgel formulation M2F1 and 
standard Pirox gel Stability studies 
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In vivo anti-inflammatory study 
The test and standard formulations exhibit anti-inflammatory effect 
for 3 h and the % inhibition of standard group at the end of 3 h is 
36.71% and that of the test group is 49.38 %. It can be concluded 
from the above results that the test formulation shows better anti-
inflammatory effect as compared to the standard group. The results 
were depicted in fig. 12. From the results, it was found that the 
optimized formulation has better ability to decrease the paw volume 
of the rat and the % inhibition was found to be more than the 
standard formulation. It can be concluded from the above results 
that the test formulation shows better anti-inflammatory effect as 
compared to the standard group. 
Formulation M2F1 showed no change in appearance after 60 d of 
storage. The pH, viscosity and percentage cumulative release 
showed the minor difference in the values so the formulations 
were found to be stable at the end of 60 d. The viscosity showed 
slight increase after 30 d at 25 °C and slight decrease at the end 
of 60th
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 day. The viscosity was found to decrease at 40 °C. The 
drug release was found to decrease as the temperature increases 
and as the day passes. The pH of the formulation was found to 
increase slightly [15]. 
CONCLUSION 
Based on saturation solubility study Oleic acid, Tween 20 and PEG 
400 were selected for the preparation of the emulsion. The emulsion 
was successfully prepared using water titration method. The 
optimized formulations of emulsion i.e. E1 and F1 showed globule 
size of 176.8 and 128 nm respectively. The emulgel formulations 
were prepared with Carbopol as gelling agent with concentrations of 
1.5% and 2% using oleic acid as penetration enhancer enhances the 
ease of application onto the skin. The prepared emulgel for topical 
application with required viscosity, spreadability, extrudability, drug 
release and stability showed better results and the optimized 
formulation showed no irritation to skin and better anti-
inflammatory result as compared to marketed one. Thus, it can be 
concluded that Meloxicam was proven to be a suitable candidate for 
formulating emulgel for topical delivery to achieve better patient 
compliance. The emulgel could help significantly to optimize the 
targeting of the drug without a concomitant increase of the systemic 
side effects. 
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